These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 20459394

  • 1. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E.
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [Abstract] [Full Text] [Related]

  • 2. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 3. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 4. Realities of newer beta-blockers for the management of hypertension.
    Manrique C, Giles TD, Ferdinand KC, Sowers JR.
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA, Black HR.
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [Abstract] [Full Text] [Related]

  • 6. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL, Saseen JJ.
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [Abstract] [Full Text] [Related]

  • 7. Use of carvedilol in hypertension: an update.
    Leonetti G, Egan CG.
    Vasc Health Risk Manag; 2012 Jun; 8():307-22. PubMed ID: 22661898
    [Abstract] [Full Text] [Related]

  • 8. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA, Bakris GL, Giles TD, Messerli FH.
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract] [Full Text] [Related]

  • 9. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
    Marazzi G, Volterrani M, Caminiti G, Iaia L, Massaro R, Vitale C, Sposato B, Mercuro G, Rosano G.
    J Card Fail; 2011 Sep; 17(9):703-9. PubMed ID: 21872138
    [Abstract] [Full Text] [Related]

  • 10. Aortic elastic properties : effects of carvedilol versus nebivolol.
    Sayin MR, Aydin M, Dogan SM, Karabag T, Cetiner MA, Aktop Z.
    Herz; 2013 May; 38(3):299-305. PubMed ID: 23263241
    [Abstract] [Full Text] [Related]

  • 11. [Nephroprotective properties of third-generation beta-adrenoblockers].
    Kuz'min OB, Belianin VV, Zhezha VV.
    Eksp Klin Farmakol; 2014 May; 77(3):40-3. PubMed ID: 24800526
    [Abstract] [Full Text] [Related]

  • 12. Nebivolol: a review.
    Cockcroft J.
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [Abstract] [Full Text] [Related]

  • 13. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD.
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [Abstract] [Full Text] [Related]

  • 14. The vasodilatory beta-blockers.
    Pedersen ME, Cockcroft JR.
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [Abstract] [Full Text] [Related]

  • 15. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M, Gupta Y, Jain S, Vardas P.
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [Abstract] [Full Text] [Related]

  • 16. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E, Rizzoni D.
    Drugs; 2007 Mar; 67(8):1097-107. PubMed ID: 17521213
    [Abstract] [Full Text] [Related]

  • 17. Nebivolol: third-generation beta-blockade.
    de Boer RA, Voors AA, van Veldhuisen DJ.
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [Abstract] [Full Text] [Related]

  • 18. [Third generation beta-blockers: current state of research on vasodilating beta-blockers].
    Ladage D, Reidenbach C, Lichtenthal A, Schwinger R, Brixius K.
    Wien Med Wochenschr; 2009 Jul; 159(7-8):211-8. PubMed ID: 19412697
    [Abstract] [Full Text] [Related]

  • 19. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 20. Arterial stiffness, hypertension, and rational use of nebivolol.
    Agabiti-Rosei E, Porteri E, Rizzoni D.
    Vasc Health Risk Manag; 2009 Oct; 5(1):353-60. PubMed ID: 19475771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.